Constantine Carmichel
Vermögen: 16 923 $ am 30.06.2026
Vermögen: 16 923 $ am 30.06.2026
Constantine Carmichel currently holds the positions of Independent Director at Futuregen Industries Corp.
since 2023, Director at WPD Pharmaceuticals, Inc. since 2023, Director at Americas Uranium Corp., and Independent Director at Mustang Energy Corp.
since 2023.
The education history includes an undergraduate degree from the University of British Columbia.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 26.03.2026 | 137’988 ( 0.25% ) | 16 835 $ | 30.06.2026 | |
| 15.04.2026 | 3’000 ( 0% ) | 48 $ | 30.06.2026 | |
0% | 06.04.2026 | 201 ( 0% ) | 40 $ | 30.06.2026 |
Gama Explorations, Inc.
Gama Explorations, Inc. Other Metals/MineralsNon-Energy Minerals Engages in exploration of copper -.--% | 04.06.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| FUTUREGEN INDUSTRIES CORP. | Direktor/Vorstandsmitglied | 17.01.2023 |
| WPD PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | 01.05.2023 |
| MUSTANG ENERGY CORP. | Direktor/Vorstandsmitglied | 28.11.2023 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Right Season Investments Corp.
Right Season Investments Corp. MiscellaneousMiscellaneous Operates as an investment issuer focused on investing growth capital into private and public companies | Miscellaneous |
University of British Columbia
University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mustang Energy Corp.
Mustang Energy Corp. Miscellaneous Commercial ServicesCommercial Services Provides trade consulting and information technology systems integration and development services | Commercial Services |
WPD Pharmaceuticals, Inc.
WPD Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as biotechnology research and development company which engages in developing oncology related medicinal products | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen